Aclaris Therapeutics, Inc. ACRS
Aclaris Therapeutics, Inc. (Nasdaq: ACRS) is an immunology/inflammation drug developer. Its lead program, Bosakitug (ATI-045), is in Phase 2 for Moderate to severe atopic dermatitis. Its next catalyst on record is Bosakitug: Phase 2 atopic dermatitis top-line data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Bosakitug — Phase 2 atopic dermatitis top-line data (Q4 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Bosakitug (ATI-045) | Atopic dermatitis | antibody | Phase 2 |
| Modzatinib (ATI-2138) | Lichen planus (Phase 2b basket planned); atopic dermatitis (Phase 2a complete) | small molecule | Phase 2 |
| Lepzacitinib (ATI-1777) | Atopic dermatitis (topical) | small molecule | Phase 2 |
| ATI-052 | Atopic dermatitis; asthma | antibody | Phase 1 |
| ATI-9494 | Immuno-inflammatory diseases | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.